Who owns WEREWOLF THERAPEUTICS INC?
- Ticker: HOWL
- CUSIP Number: 95075a107
Tip: Access positions for across all investors
Analyze quarterly positions in Werewolf Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Werewolf Therapeutics stock
Who bought or sold WEREWOLF THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| RA Capital Management | 6.1M | $40M | 0% | Mar 2024 |
|
| MPM Asset Management | 4.3M | $28M | 0% | Mar 2024 |
|
| Partner Fund Management | 3.5M | $13M | 36% | Dec 2023 |
|
| Adage Capital Partners GP | 3.0M | $19M | 200% | Mar 2024 |
|
| MPM Oncology Impact Management | 2.4M | $16M | 0% | Mar 2024 |
|
| Bank of America Corporation | 1.9M | $12M | -10% | Mar 2024 |
|
| Henderson Group | 1.7M | $11M | 100% | Mar 2024 |
|
| Rubric Capital Management | 1.6M | $11M | -16% | Mar 2024 |
|
| Vanguard Group | 1.1M | $7.2M | 27% | Mar 2024 |
|
| Monashee Investment Management | 890k | $5.8M | 100% | Mar 2024 |
|
| Eagle Health Investments | 700k | $4.5M | 100% | Mar 2024 |
|
| Sphera Funds Management | 627k | $4.1M | 0% | Mar 2024 |
|
| Verition Fund Management | 572k | $3.7M | 100% | Mar 2024 |
|
| Millennium Management | 565k | $3.7M | 27% | Mar 2024 |
|
| Geode Capital Management | 260k | $1.7M | 49% | Mar 2024 |
|
| Two Sigma Advisers | 248k | $1.6M | 40% | Mar 2024 |
|
| Alyeska Investment Group | 236k | $1.5M | -46% | Mar 2024 |
|
| Susquehanna International | 204k | $1.3M | 100% | Mar 2024 |
|
| Laurion Capital Management | 201k | $1.3M | 154% | Mar 2024 |
|
| Two Sigma Investments | 185k | $1.2M | 26% | Mar 2024 |
|
| Acadian Asset Management | 173k | $1.1M | 120% | Mar 2024 |
|
| Goldman Sachs Group | 173k | $1.1M | 100% | Mar 2024 |
|
| BlackRock | 165k | $1.1M | 114% | Mar 2024 |
|
| Jane Street | 157k | $1.0M | 985% | Mar 2024 |
|
| Qube Research & Technologies | 117k | $758k | 5850550% | Mar 2024 |
|
| Dimensional Fund Advisors | 112k | $723k | 77% | Mar 2024 |
|
| Bridgeway Capital Management | 85k | $551k | -11% | Mar 2024 |
|
| Man Group | 80k | $516k | 100% | Mar 2024 |
|
| Citigroup | 72k | $464k | 100% | Mar 2024 |
|
| Jpmorgan Chase & Co | 71k | $461k | 85664% | Mar 2024 |
|
| Edgewood Management | 50k | $324k | 0% | Mar 2024 |
|
| Northern Trust | 49k | $314k | 86% | Mar 2024 |
|
| Cubist Systematic Strategies | 41k | $263k | 100% | Mar 2024 |
|
| Hrt Financial | 38k | $243k | 100% | Mar 2024 |
|
| Royce & Associates | 37k | $242k | 100% | Mar 2024 |
|
| Denali Advisors | 27k | $172k | 100% | Mar 2024 |
|
| Marshall Wace | 26k | $170k | 100% | Mar 2024 |
|
| ExodusPoint Capital Management | 25k | $164k | 100% | Mar 2024 |
|
| American Century Companies | 25k | $162k | 100% | Mar 2024 |
|
| Squarepoint Ops | 25k | $159k | 100% | Mar 2024 |
|
| Raymond James Financial Services Advisors | 24k | $153k | 100% | Mar 2024 |
|
| Point72 Asia | 23k | $151k | 100% | Mar 2024 |
|
| Balyasny Asset Management | 23k | $149k | 100% | Mar 2024 |
|
| Morgan Stanley | 21k | $133k | 723% | Mar 2024 |
|
| Brevan Howard Capital Management | 19k | $123k | 100% | Mar 2024 |
|
| Y-Intercept | 14k | $92k | 100% | Mar 2024 |
|
| HBK Sorce Advisory | 13k | $86k | -50% | Mar 2024 |
|
| Citadel Advisors | 13k | $83k | -50% | Mar 2024 |
|
| Tower Research Capital | 11k | $68k | 348% | Mar 2024 |
|
| Camden Capital | 10k | $39k | 100% | Dec 2023 |
|
| Financial Perspectives | 6.8k | $44k | 0% | Mar 2024 |
|
| Barclays | 1.9k | $12k | 100% | Mar 2024 |
|
| Baystate Wealth Management | 300.00 | $1.2k | 100% | Dec 2023 |
|
| Simplex Trading | 202.00 | $1.0k | -96% | Mar 2024 |
|
| Wells Fargo & Company | 194.00 | $1.3k | 26% | Mar 2024 |
|
| Royal Bank of Canada | 42.00 | $0 | 100% | Mar 2024 |
|
| UBS Group | 37.00 | $240.000500 | -96% | Mar 2024 |
|
Who sold out of Werewolf Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Virtu Financial | Dec 2023 | 20k | $79k |